Lucera Erick
SEC-identified person · CIK 1697616 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Dyne Therapeutics, Inc. DYN | Chief Financial Officer | filed 2025 - 2026 |
| SAB Biotherapeutics, Inc. SABS | Director | filed 2023 - 2025 |
| Beyond Air, Inc. XAIR | Director | filed 2018 - 2025 |
| Editas Medicine, Inc. EDIT | EVP, CHIEF FINANCIAL OFFICER | filed 2023 - 2025 |
| Bone Biologics, Corp. BBLG | Director | filed 2021 - 2023 |
| Aveo Pharmaceuticals, INC. AVEO | Chief Financial Officer | filed 2020 - 2023 |
| Valeritas Holdings Inc. VLRX | See Remarks | filed 2017 - 2019 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.